SCHEMBL21824020

SCHEMBL21824020

Cc1nc(-c2cnc3n(c2=O)CCN3C)ccc1Oc1ccnc(-c2cnn(C)c2)c1

nearest known ligand 0.68

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
▸ CSF1R P07333 20/20 0.68
▸ PDGFRA P16234 12/20 0.68
▸ PDGFRB P09619 5/20 0.68
▸ FLT3 P36888 4/20 0.68
▸ KIT P10721 3/20 0.68
▸ CYP2C9 P11712 2/20 0.68
▸ LCK P06239 1/20 0.68
▸ PTK6 Q13882 1/20 0.68
▸ KDR P35968 2/20 0.66
▸ MET P08581 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21824034 0.95 CSF1R (0.69) CSF1RPDGFRAPDGFRBFLT3KIT
SCHEMBL21824035 0.88 CSF1R (0.66) CSF1RPDGFRAPDGFRBFLT3KIT
SCHEMBL21823997 0.87 CSF1R (0.72) CSF1RPDGFRAPDGFRBFLT3KIT
SCHEMBL21824000 0.87 CSF1R (0.65) CSF1RPDGFRAPDGFRBFLT3KIT
SCHEMBL16046106 0.86 CSF1R (0.73) CSF1RPDGFRAPDGFRBFLT3KIT
SCHEMBL30673537 0.86 CSF1R (0.64) CSF1RPDGFRAPDGFRBFLT3KIT
SCHEMBL21824032 0.86 CSF1R (0.64) CSF1RPDGFRAPDGFRBFLT3KIT
SCHEMBL21824028 0.86 CSF1R (0.62) CSF1RPDGFRAPDGFRBFLT3KIT
SCHEMBL31741155 0.85 CSF1R (0.78) CSF1RPDGFRAPDGFRBFLT3KIT
SCHEMBL21824031 0.85 CSF1R (0.64) CSF1RPDGFRAPDGFRBFLT3KIT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3632906-B1 AZAARYL DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF FOR USE IN PHARMACY ABBISKO THERAPEUTICS CO LTD (CN) 2023-12-13 — — EP disclosed
EP-3632906-B1 AZAARYL DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF FOR USE IN PHARMACY ABBISKO THERAPEUTICS CO LTD (CN) 2023-12-13 — — EP disclosed
US-11130762-B2 Azaaryl derivative, preparation method therefor, and application thereof for use in pharmacy ABBISKO THERAPEUTICS CO., LTD. (CN) 2021-09-28 — — US disclosed
US-11130762-B2 Azaaryl derivative, preparation method therefor, and application thereof for use in pharmacy ABBISKO THERAPEUTICS CO., LTD. (CN) 2021-09-28 — — US disclosed
US-20200165254-A1 AZAARYL DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF FOR USE IN PHARMACY ABBISKO THERAPEUTICS CO., LTD. (CN) 2020-05-28 — — US disclosed
US-20200165254-A1 AZAARYL DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF FOR USE IN PHARMACY ABBISKO THERAPEUTICS CO., LTD. (CN) 2020-05-28 — — US disclosed
EP-3632906-A1 AZAARYL DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF FOR USE IN PHARMACY Abbisko Therapeutics Co., Ltd. (CN) 2020-04-08 — — EP disclosed
EP-3632906-A1 AZAARYL DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF FOR USE IN PHARMACY Abbisko Therapeutics Co., Ltd. (CN) 2020-04-08 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200165254-A1 AZAARYL DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF FOR USE IN PHARMACY FAR1, CSF1R, CSF3R CSF1R 2/4885PDGFRA 977/4885PDGFRB 891/4885
US-11130762-B2 Azaaryl derivative, preparation method therefor, and application thereof for use in pharmacy FAR1, CSF1R, CSF3R CSF1R 2/4885PDGFRA 977/4885PDGFRB 891/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback